Bernd Neumaier

Summary

Affiliation: University of Cologne
Country: Germany

Publications

  1. ncbi Short Communication: (18)F-immuno-PET: Determination of anti-CD66 biodistribution in a patient with high-risk leukemia
    Bernd Neumaier
    Department of Nuclear Medicine, University of Ulm, Germany
    Cancer Biother Radiopharm 23:819-24. 2008
  2. ncbi Synthesis and evaluation of 18F-fluoroethylated benzothiazole derivatives for in vivo imaging of amyloid plaques in Alzheimer's disease
    B Neumaier
    Department of Nuclear Medicine, University of Ulm, Ulm, Germany
    Appl Radiat Isot 68:1066-72. 2010
  3. ncbi Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma
    Markus Luster
    Department of Nuclear Medicine, University of Ulm, Germany
    Thyroid 20:527-33. 2010
  4. ncbi Clinical relevance of imaging proliferative activity in lung nodules
    Andreas K Buck
    Department of Nuclear Medicine, University of Ulm, Robert Koch Strasse 8, 89081, Ulm, Germany
    Eur J Nucl Med Mol Imaging 32:525-33. 2005
  5. ncbi Molecular imaging of proliferation in malignant lymphoma
    Andreas K Buck
    Department of Nuclear Medicine, Institute of Pathology, University Hospital Ulm, Ulm, Germany
    Cancer Res 66:11055-61. 2006
  6. ncbi 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease
    Martin Wagner
    Department of Nuclear Medicine, University of Ulm, 89081 Ulm, Germany
    Cancer Res 63:2681-7. 2003
  7. ncbi Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation
    Thorsten Zenz
    Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
    J Nucl Med 47:278-86. 2006
  8. ncbi Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT
    Andreas K Buck
    Department of Nuclear Medicine, University Hospital Ulm, Ulm, Germany
    Eur J Nucl Med Mol Imaging 34:1775-82. 2007
  9. ncbi Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG
    Andreas K Buck
    Department of Nuclear Medicine, University of Ulm, Ulm, Germany
    J Nucl Med 44:1426-31. 2003
  10. ncbi Imaging prostate cancer with 11C-choline PET/CT
    Sven N Reske
    Department of Nuclear Medicine, University of Ulm, Ulm, Germany
    J Nucl Med 47:1249-54. 2006

Collaborators

Detail Information

Publications22

  1. ncbi Short Communication: (18)F-immuno-PET: Determination of anti-CD66 biodistribution in a patient with high-risk leukemia
    Bernd Neumaier
    Department of Nuclear Medicine, University of Ulm, Germany
    Cancer Biother Radiopharm 23:819-24. 2008
    ..Nevertheless, PET-based dosimetry with [(18)F]F-anti-CD66 could provide additional information to support conventional scintigraphy. Moreover, [(18)F]F-anti-CD66 is ideally suited for bone marrow imaging using PET...
  2. ncbi Synthesis and evaluation of 18F-fluoroethylated benzothiazole derivatives for in vivo imaging of amyloid plaques in Alzheimer's disease
    B Neumaier
    Department of Nuclear Medicine, University of Ulm, Ulm, Germany
    Appl Radiat Isot 68:1066-72. 2010
    ....
  3. ncbi Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma
    Markus Luster
    Department of Nuclear Medicine, University of Ulm, Germany
    Thyroid 20:527-33. 2010
    ..The aim of this study was therefore to test the hypothesis that combined (18)F-DOPA PET/CT more accurately detects MTC lesions than each modality does alone...
  4. ncbi Clinical relevance of imaging proliferative activity in lung nodules
    Andreas K Buck
    Department of Nuclear Medicine, University of Ulm, Robert Koch Strasse 8, 89081, Ulm, Germany
    Eur J Nucl Med Mol Imaging 32:525-33. 2005
    ..In this prospective study, we examined the accuracy of FLT for differentiation of benign from malignant lung lesions and for tumour staging...
  5. ncbi Molecular imaging of proliferation in malignant lymphoma
    Andreas K Buck
    Department of Nuclear Medicine, Institute of Pathology, University Hospital Ulm, Ulm, Germany
    Cancer Res 66:11055-61. 2006
    ....
  6. ncbi 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease
    Martin Wagner
    Department of Nuclear Medicine, University of Ulm, 89081 Ulm, Germany
    Cancer Res 63:2681-7. 2003
    ..These results suggest that [(18)F]-FLT represents a novel tracer for PET that enables imaging of proliferation in human lymphoma in vivo...
  7. ncbi Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation
    Thorsten Zenz
    Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
    J Nucl Med 47:278-86. 2006
    ....
  8. ncbi Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT
    Andreas K Buck
    Department of Nuclear Medicine, University Hospital Ulm, Ulm, Germany
    Eur J Nucl Med Mol Imaging 34:1775-82. 2007
    ....
  9. ncbi Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG
    Andreas K Buck
    Department of Nuclear Medicine, University of Ulm, Ulm, Germany
    J Nucl Med 44:1426-31. 2003
    ..In this prospective study, we examined whether (18)F-FLT better determines proliferative activity in newly diagnosed lung nodules than does (18)F-FDG...
  10. ncbi Imaging prostate cancer with 11C-choline PET/CT
    Sven N Reske
    Department of Nuclear Medicine, University of Ulm, Ulm, Germany
    J Nucl Med 47:1249-54. 2006
    ....
  11. ncbi Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma
    Felix M Mottaghy
    Department of Nuclear Medicine, University Hospital Ulm, Robert Koch Strasse 8, 89073, Ulm, Germany
    Eur J Nucl Med Mol Imaging 34:1355-64. 2007
    ..The purpose of this retrospective, blinded study was to evaluate the additional value of [18F]FDG PET/CT in comparison with PET alone and with side-by-side PET and CT in patients with malignant melanoma (MM)...
  12. ncbi Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia
    Gerhard Glatting
    Department of Nuclear Medicine, University Ulm, Ulm, Germany
    J Nucl Med 47:1335-41. 2006
    ..We evaluated the biodistribution of 111In-labeled anti-CD45 antibody in humans using the rat IgG2a monoclonal antibody YAML568 that recognizes a common CD45 epitope present on all human leukocytes...
  13. ncbi Synthesis and evaluation of a radiometal-labeled macrocyclic chelator-derivatised thymidine analog
    Michaela Schmid
    Department of Nuclear Medicine, University Hospital Ulm, 89081 Ulm, Germany
    Nucl Med Biol 33:359-66. 2006
    ..The absence of substrate specificity may be due to the bulky macrocyclic chelator and partial charges remaining on the coordination sphere due to a more complex solution structure...
  14. ncbi Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer
    Jorg Kotzerke
    Department of Nuclear Medicine, University of Ulm, Germany
    Eur J Nucl Med Mol Imaging 29:1380-4. 2002
    ..0 ng/ml ( n=8), five patients had positive PET findings, with four of them verified by biopsy. It is concluded that [(11)C]acetate PET is a promising new tool for the diagnosis of PCA recurrence and can influence patient management...
  15. ncbi Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma
    Markus Luster
    Department of Nuclear Medicine, University of Ulm, Albert Einstein Allee 23, 89081, Ulm, Germany
    Eur J Nucl Med Mol Imaging 37:484-93. 2010
    ..The aim of this study was to investigate whether combined (18)F-DOPA PET/CT more accurately detects and localizes PHEO lesions than does each modality alone...
  16. ncbi 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study
    Mark Ringhoffer
    Department of Internal Medicine III, University of Ulm, Ulm, Germany
    Br J Haematol 130:604-13. 2005
    ..In conclusion, radioimmunotherapy using the anti-CD66 antibody was feasible and safe in our elderly patient group and provided a high marrow dose...
  17. ncbi 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules
    Andreas K Buck
    Department of Nuclear Medicine, Universit of Ulm, Germany
    Cancer Res 62:3331-4. 2002
    ..0001; r = 0.87). FLT uptake was specific for malignant lesions and may be used for differential diagnosis of SPNs, assessment of proliferation, and estimation of prognosis...
  18. ncbi Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib
    Carsten Kobe
    Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany
    Eur J Nucl Med Mol Imaging 39:1117-27. 2012
    ....
  19. ncbi [18F]3'-deoxy-3'-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations--a pilot study
    Inga Buchmann
    Nuklearmedizin, Universitatskliniken, Ulm, Germany
    Cancer Biother Radiopharm 19:436-42. 2004
    ..We prospectively evaluated the biodistribution of the PET tracer [18F]3'-deoxy-3'-fluorothymidine (FLT) and its value in detecting manifestations of non-Hodgkin's lymphoma (NHL)...
  20. ncbi Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[(18)F]fluoro-3'-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines
    Ulrike Seitz
    Department of Nuclear Medicine, University of Ulm, Robert Koch Strasse 8, 89081 Ulm, Germany
    Eur J Nucl Med Mol Imaging 29:1174-81. 2002
    ..Thus, we propose [(18)F]FLT as a promising tracer for positron emission tomography that might overcome current limitations in the diagnosis of pancreatic cancer...
  21. ncbi Imaging of activated microglia with PET and [11C]PK 11195 in corticobasal degeneration
    Karsten Henkel
    Department of Neurology, University of Ulm, Ulm, Germany
    Mov Disord 19:817-21. 2004
    ..11)C]PK 11195 PET suggests involvement of microglial activation in the pathogenesis of CBD...
  22. ncbi PET for prostate cancer imaging: still a quandary or the ultimate solution?
    Jorg Kotzerke
    University of Ulm, Germany
    J Nucl Med 43:200-2. 2002